chronic kidney disease
-
Once a Blockbuster Prospect, Is Travere’s Kidney Drug on Track to Become a Bust?
Seven months after Travere Therapeutics’ flagship drug received accelerated FDA approval in a rare kidney disease, the molecule has fallen short of the key goal of its confirmatory test. It’s the small molecule’s second Phase 3 failure this year.
-
Strive Health, Oak Street Health Strike Kidney Care Partnership
Kidney care company Strive Health announced last week that it is collaborating with primary care company Oak Street Health to serve Medicare members with stage 4 chronic kidney disease and end-stage kidney disease.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Humana Taps Interwell Health for Kidney Care
In a new agreement, Interwell Health will provide care to Humana Medicare Advantage HMO and PPO members with chronic kidney disease in 13 states. It will also serve patients with end-stage kidney disease across the country.
-
Emergency Dialysis: A Crutch for Fee-For-Service Healthcare
Physicians often diagnose patients with chronic kidney disease (CKD) too late in the process, when dialysis is the only option left. This isn’t negligence on the part of physicians — it’s simply a consequence of a fee-for-service (FFS) healthcare model that works against patients’ financial well-being and deemphasizes preventative care.
-
Signify Health Unveils Chronic Kidney Disease Evaluation
Home care company Signify Health announced Tuesday that it added an in-home kidney health evaluation to its platform. Based on the results of the evaluation, the company can refer patients to their primary care physician or a specialist if they’re in need of further treatment.
-
MedCity Influencers, Artificial Intelligence
The Case for Automatic Surveillance during Dialysis
This lack of monitoring is a serious problem—both for patients and for the overall healthcare system. The data show that in a typical dialysis center, each patient will suffer an average of 1.7 access blockages per year.
-
GSK Gets FDA Nod for Drug Treating Anemia From Chronic Kidney Disease
The FDA approved GSK drug Jesduvroq for treating anemia in patients with chronic kidney disease. The once-daily pill is the first oral medicine to pass FDA muster in this indication, giving patients a more convenient alternative to injectable anemia therapies.
-
Lessons learned from prison and dialysis while trying to prevent the pain, loss and cost of kidney diseases
These two health care settings provided invaluable lessons: get ahead of the curve through collaboration with other doctors, better monitoring, early referrals, and education.
-
MedCity Influencers, BioPharma, Opinion
Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.?
Kidney disease patients need access to innovative therapies to expand treatment choices and improve quality of life. The FDA should closely examine whether it is applying the appropriate benefit/risk assessment for new drugs intended for this population.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
MedCity Influencers, Devices & Diagnostics
The medtech industry’s responsibility in addressing the socioeconomic barriers to accessing and succeeding on renal replacement therapy
Aside from rallying for more patient-oriented reimbursement and removing the red tape involved so that providers can provide home-based dialysis care, medical device manufacturers must also offer a turnkey solution for home-based therapy that includes servicing the device in a door-to-door model.
-
Claiming Akebia agreement breach, Otsuka seeks to end anemia drug pact
Otsuka Pharmaceutical is ending its alliance with Akebia Therapeutics, a move that comes less than two months after the FDA rejected their partnered anemia drug, vadadustat, and asked for another clinical trial. Otsuka alleges unspecified breaches of the agreement by Akebia, and ending the alliance early could spare it from spending hundreds of millions of dollars more on the drug.
-
Safety concerns sink Akebia drug for anemia from chronic kidney disease
The FDA rejected Akebia Therapeutics drug vadadustat as a treatment for anemia caused by chronic kidney disease. According to the biotech, the agency cited safety concerns and asked for another clinical trial to show that the pill’s benefits outweigh its risks.
-
Executives at new InterWell Health, formed by 3-way merger, want to turn kidney care on its head
The new organization combining InterWell, Fresenius Health Partners and Cricket Health is valued at $2.4 billion with a total addressable market of $170 billion, more than $6 billion of medical costs under management, and over 100,000 covered lives, according to the combined company.
-
MedCity Influencers, Health Tech, Physicians
How to ensure Medicare’s kidney care contracting model succeeds — and transform treatment
Medicare’s Comprehensive Kidney Care Contracting model spotlights the importance of proactive, coordinated kidney care. It’s critical for nephrology practices to start incorporating this patient-centric approach and consider more than just immediate kidney concerns.
-
FDA rejects Reata Pharma chronic kidney disease drug; new trial needed
The FDA told Reata that the clinical data do not show that the drug, bardoxolone, slows the progression of the loss of kidney function in patients who have the rare disease Alport syndrome. The regulatory decision follows an FDA advisory committee vote recommending against approval of the small molecule drug.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
